Drug-eluting material systems have proven useful in a variety of clinical settings, including preventing restenosis with stenting, treating cancer and enhancing wound healing. These systems benefit from tunable drug release kinetics, continuous drug release, and local delivery, which together provide spatiotemporal control over drug availability and diminish drug toxicity. I will describe our efforts to overcome one major hurdle to widespread use of drug-eluting systems in vivo – that they carry a finite depot of drug and require invasive procedures to refill. I will describe a technology to modify materials so as to capture blood-circulating drug refills, allowing for repeated refilling of the depots for local release. Bioorthogonal chemistry and nucleic acid-based methods for selective depot replenishment will be discussed. Repeated drug refilling and release improved outcomes in cancer models and allowed for selective drug homing in models of lower limb ischemia and osteomyelitis. Refillable drug delivery devices that enable repeated and spatiotemporally controlled drug release may have clinical applications in cancer therapy, wound healing, immunotherapy, and drug-eluting vascular grafts and stents.

Refilling drug-eluting depots through systemic administration of inert prodrugs

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.